From Medscape Oncology

Coverage from the

European Society for Medical Oncology (ESMO) Annual Meeting 2023

October 20 - 24, 2023; Madrid, Spain and Virtual/Online

October 20 - 24, 2023 Madrid, Spain and Virtual/Online

ESMO 2023 'We Finally Made It': Amivantamab Comes of Age in NSCLC Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings.
Medscape Medical News, October 25, 2023
ESMO 2023 Enzalutamide Ups Mets-Free Survival, QoL in Prostate Cancer Enzalutamide plus androgen deprivation therapy or alone can extend metastasis-free survival and maintain quality of life in men with prostate cancer facing a high-risk for biochemical recurrence.
Medscape Medical News, October 23, 2023
ESMO 2023 Perioperative Nivolumab Improves EFS in Resectable NSCLC Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.
Medscape Medical News, October 21, 2023

Register today to get unlimited access to Medscape's conference coverage, medical news and CME. Meet us at the Medscape Oncology stand #589, Hall 5 at ESMO Annual Meeting 2023.

Conference News

ESMO 2023 T-DXd Benefits Persist for HER2-Low Breast Cancer
MDedge News, November 9, 2023
ESMO 2023 Benefits of Tebentafusp in Uveal Melanoma Last 3 Years
Medscape Medical News, November 7, 2023
ESMO 2023 Selpercatinib Extends PFS in First-line RET-Positive NSCLC
Medscape Medical News, November 6, 2023
ESMO 2023 How Can We Improve Our Approach to Cancer-Related Fatigue?
Medscape Medical News, November 6, 2023
ESMO 2023 Omitting Surgery May Be Safe in Early BC After pCR
MDedge News, November 3, 2023
ESMO 2023 ADC Shows Survival Benefit in Mets Cervical Cancer
MDedge News, November 2, 2023
ESMO 2023 PD-1 Inhibitor Improves Outcomes in NHL Subtype
MDedge News, November 1, 2023
ESMO 2023 Ocular MALT Lymphoma: Radiation Reduces Relapse
MDedge News, October 30, 2023
ESMO 2023 Induction Chemo Extends Survival in Cervical Cancer
MDedge News, October 27, 2023
ESMO 2023 Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On
Medscape Medical News, October 26, 2023
ESMO 2023 'We Finally Made It': Amivantamab Comes of Age in NSCLC
Medscape Medical News, October 25, 2023
ESMO 2023 Investigational ADC Improves PFS in Metastatic Breast Cancer
MDedge News, October 25, 2023
ESMO 2023 'Why Did I Choose This?' Tackling Burnout in Oncology
Medscape Medical News, October 24, 2023
ESMO 2023 The Sobering Facts About Alcohol and Cancer
Medscape Medical News, October 24, 2023

ESMO 2023 Enzalutamide Ups Mets-Free Survival, QoL in Prostate Cancer
Medscape Medical News, October 23, 2023
ESMO 2023 ICIs Improve pCR Rates in Early ER+/HER2– Breast Cancer
MDedge News, October 23, 2023
ESMO 2023 No Benefit to Adding ICI to Chemo in TNBC
MDedge News, October 23, 2023
ESMO 2023 Does Adding Pembro Improve PFS in High-Risk Cervical Cancer?
MDedge News, October 22, 2023
ESMO 2023 Double Good, Triple Therapy Better in Endometrial Cancer?
Medscape Medical News, October 22, 2023
ESMO 2023 ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC
Medscape Medical News, October 22, 2023
ESMO 2023 Perioperative Nivolumab Improves EFS in Resectable NSCLC
Medscape Medical News, October 21, 2023
ESMO 2023 Remote Symptom Monitoring in Advanced Cancer Improves QoL
Medscape Medical News, October 21, 2023
ESMO 2023 Long-Term Benefits of Adjuvant Abemaciclib in Breast Cancer
MDedge News, October 21, 2023
ESMO 2023 Observation, Not Radiotherapy, After Radical Prostatectomy
Medscape Medical News, October 20, 2023
ESMO 2023 Fasting During Breast Cancer Chemo Improves Quality of Life
Medscape Medical News, October 20, 2023
ESMO 2023 Can Some Patients With Esophageal Cancer Avoid Surgery?
Medscape Medical News, October 20, 2023
ESMO 2023 ESMO 2023: A Wealth of New Data Across Cancer Types
Medscape Medical News, October 11, 2023

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Highlights in Metastatic Breast Cancer From ESMO 2023
Ann H. Partridge, MD, MPH
Highlights in Early Breast Cancer From ESMO 2023
Lisa A. Carey, MD
Non-Small Cell Lung Cancer Highlights From ESMO 2023
Enriqueta Felip, MD, PhD
Renal Cell Carcinoma Highlights From ESMO 2023
Brian Rini, MD
Practice-Changing Data in Prostate Cancer From ESMO 2023
Oliver Sartor, MD
ESMO 2023: The Impact of New Data on Patient Care
Rana R. McKay, MD
ESMO 2023: Reflecting on New Data in Advanced NSCLC
Julia Rotow, MD
Highlights in Endometrial Cancer From ESMO 2023
Susana Banerjee, MBBS, MA, PhD
Key Updates in Ovarian Cancer From ESMO 2023
Susana Banerjee, MBBS, MA, PhD
Key Trial Data in Genitourinary Cancers From ESMO 2023
Viktor Grünwald, MD
ESMO 2023: Key Highlights in Advanced NSCL
Julia Rotow, MD
ESMO 2023: Advancing Prostate Cancer Care
Rana R. McKay, MD
ESMO 2023: Looking Forward to Fresh Data for Advanced NSCLC
Julia Rotow, MD
ESMO 2023: Anticipating Advances in Prostate Cancer Research
Rana R. McKay, MD

Oncology Education Services

Empower Yourself with CE-CME-CPD Accredited Free Oncology Courses. Boost your clinical skills and keep your learning up to date. Access now.

Popular News From ESMO 2022

'Unprecedented' Responses to Neoadjuvant Tx in dMMR Colon Cancer An 'innovative' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved 'unprecedented' pathologic responses, with no recurrences.
Medscape Medical News, Sep 11, 2022
Time to Cancer Diagnoses: 5-Month Average Wait But almost 16% of patients in the US waited 6 months or longer for a diagnosis.
Medscape Medical News, Sep 19, 2022
Blood Test for Multiple Cancers: Many False Positives More results from the Pathfinder trial of the Galleri blood test for multiple cancers show that the test does detect cancer in healthy individuals, but it also has false positive results.
Medscape Medical News, Sep 11, 2022

Previous Coverage